Immuron Ltd — Investor Presentation 2015

Aug 18, 2015

==> picture [192 x 54] intentionally omitted <==

Immuron Commences US Investor Roadshow

19 August 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) today wishes to announce that the Company has commenced a US Investor Roadshow where the Company will showcase its technology platform and profile to US investment groups.

This US Roadshow comes off the back of recent market announcements detailing the Company’s advances in all product areas of the business, Travelan, NASH, ASH, C-Diff, and now Protectyn.

Travelan:

Immuron announced the execution of a 50,000 minimum annual order supply agreement for the Company’s flagship product, Travelan with the major US Travel Clinic supplier, Traveler’s Supply Inc.

NASH and ASH Clinical Trials:

The Company’s Clinical Trials are progressing well and have been further bolstered by the Company’s recent appointments of SVP of Innovation Dr Dan Peres, and Chief Operating and Scientific Officer Dr Jerry Kanellos.

A recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35 - $40 billion. The high prevalence of Type 2 diabetes and obesity, which lead to NASH and other non-alcoholic fatty liver diseases (NAFLD), boosts the prevalence of NASH and its market growth.

A copy of the US Investor Roadshow Presentation has been attached below.

Contacts:

Dr Roger Aston Amanda Loh Non-Executive Chairman Buchan Consulting +61 (0)3 9824 5254 +61 (0)3 9866 4722

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers’ diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045

AUGUST 2015

HEALTH TO CHEW ON

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

prevention of disease.
----- End of picture text -----

NASH/ASH

SUMMARY

TRAVELAN

PIPELINE

2

TRAVELAN®

PIPELINE

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH/ASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Immuron presents the large upside Investor Potential of a biotech company.

It has a unique natural immune-technology platform with GRAS status that significantly reduces the research to product cycle timelines.

Immuron has a revenue-generating product with multiple revenue pathways

3

TRAVELAN®

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH/ASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

NASH: Two Phase II studies in progress with ASH: an increasingly alluring potential upside Travelan: Revenues growing and positioned to grow further with successful USA launch

Pipeline: Progressing and Strong Cap Pofile: Robust

Financials: Debt free, cash in the bank until after completion of NASH trial

4

TRAVELAN®

NASH/ASH

PIPELINE

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

AUD$19.5M

Listed Unlisted ASX Code: IMC Shares Options Options Securities currently on ~75M ~3M ~ 6M

Rank Shareholder Name Qty Held % Ownership	Rank Shareholder Name Qty Held % Ownership
1
2	AUTHENTICS AUSTRALIA PTY LTD 4,999,999 6.67%
3
4	MR PETER ANASTASIOU & 2,907,236 3.88%
5
6	FIFTY-FIFTH LEPRECHAUN PTY LTD 2,035,371 2.72%
7
8	INSYNC INVESTMENTS PTY LTD 1,534,432 2.05%
9
10	MR DAVID ANTHONY PLUSH & 1,334,075 1.78%
11
12	G & N LORD SUPERANNUATION PTY 1,237,994 1.65%
13
14	JOJO ENTERPRISES PTY LTD 918,898 1.23%
15
16	CAPITAL CONCERNS PTY LIMITED 654,716 0.87%
17
18	MR HAMISH SALMON & 575,000 0.77%
19
20	ADVANCE CLINICAL SYSTEMS 546,874 0.73%

5

NASH/ASH

TRAVELAN

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Targeting the human immune system with natural antibodies derived from bovine to address diseases of the gut and liver.

Why?

Acute and chronic infections in the gut have a major impact in human health, causing dis biosis and many metabolic diseases.

6

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

• Attractive risk-reward ratio – biotech upside with reduced risk profile

Immuron’s Platform Products

• Natural product

• High safety profile

• Not a binary outcome.

• If clinical end points not attained, there may still be a product that generates revenue

• Low Cost

Other Products

� Synthetic product � Side effects occur

� Binary outcome: clinical trial failure means there is no product

� Antibodies typically very expensive to make

7

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [175 x 25] intentionally omitted <==

----- Start of picture text -----

NASH PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Pathway with reduced risk

==> picture [472 x 357] intentionally omitted <==

----- Start of picture text -----

Traditional model Immuron’s De-risked Platform
Pre-clinical
Phase I clinical
OR
OTC Consumers
Phase II clinical
OR
OTC Consumers
Phase III clinical
OR
Medical Food
Prescribed drug
on the market
----- End of picture text -----

==> picture [11 x 14] intentionally omitted <==

----- Start of picture text -----

8
----- End of picture text -----

2.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
Stop it before it starts
----- End of picture text -----

SUMMARY

OVERVIEW

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

PIPELINE

==> picture [637 x 117] intentionally omitted <==

----- Start of picture text -----

Without Travelan [®] : Bacteria With Travelan [®] : Bacteria
----- End of picture text -----

10

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

http://www.travelan.com.au

`

Traveller’s diarrhoea global market estimate: US$600M - 1.2B

All-natural product; clinically proven with very high safety profile Available over-the-counter Strong brand loyalty

11

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Growing Australian brand

==> picture [203 x 136] intentionally omitted <==

12

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Successfully Launched in the USA

==> picture [203 x 136] intentionally omitted <==

==> picture [136 x 82] intentionally omitted <==

• ** Note: first non-exclusive distribution contract signed for 50,000 units in July 2015 with major Traveller’s Supply company at full margin.

13

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [175 x 25] intentionally omitted <==

----- Start of picture text -----

NASH PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Status in Nov 2013

Progress in 2015

Country Discussions Term Sheet Licensed Regulatory In Market Canada South Korea Other Asian Countries US (partnered) No regulatory process United States (direct) India China

• Regulatory application preceding partnering engagement

14

3.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

NASH/ASH
(INFLAMED
FATTY LIVER)
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [83 x 55] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

Lipotoxicity

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Cirrhosis: Severe liver damage Liver Fibrosis: Scarring of liver tissue NASH: Inflamed Fatty Liver Liver: Fat accumulation We eat badly and are too sedentary

PIPELINE

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

TRAVELAN

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Population = 100%

Cirrhosis; 1 in 10

NASH > 5%

NAFL~ 25%

OVERVIEW TRAVELAN NASH/ASH PIPELINE SUMMARY

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

= Estimated $40B Market in 2025
NASH - The Next Big Global Epidemic in 10 Years?
Deutsche Bank, Markets Research, 14 July 2014
----- End of picture text -----

OVERVIEW TRAVELAN NASH/ASH PIPELINE SUMMARY

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

IMM-124E chosen by NIH from
27 candidates for a phase II
study in ASH. Currently
recruiting.
----- End of picture text -----

OVERVIEW TRAVELAN NASH/ASH PIPELINE SUMMARY

==> picture [721 x 271] intentionally omitted <==

OVERVIEW

TRAVELAN

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

==> picture [126 x 82] intentionally omitted <==

==> picture [377 x 26] intentionally omitted <==

----- Start of picture text -----

�
IMM-124E is safe and may be best in class
----- End of picture text -----

Prevents bacterial spread

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

2 Phase II trials started and recruiting

NASH- IMMURON FUNDED

ASH- NIH FUNDED

Phase II trial has begun:

Phase II trial has begun:

NIH funded,

22

==> picture [211 x 299] intentionally omitted <==

Princess Alexandra Hospital, Brisbane, QLD

==> picture [71 x 57] intentionally omitted <==

Westmead Hospital, Sydney, NSW Nepean Hospital, Sydney, NSW Box Hill Hospital Melbourne, VIC

Alfred Hospital

Swedish MC Seattle, WA

==> picture [180 x 170] intentionally omitted <==

U.Colorado, Denver, CO

Cleveland Clinic, OH

==> picture [53 x 44] intentionally omitted <==

==> picture [83 x 50] intentionally omitted <==

Kansas City GE&H, MO

UVA, Charlottesville VA VCU, Richmond VA Bon Secours, Richmond/NN, VA

Duke Liver Center, Durham NC

U Florida, Gainesville, FL

Baylor St Luke’s Houston, TX

24

OVERVIEW

TRAVELAN

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

SUMMARY

Bile Acid

Shire - LUM-002

Intercept - Obeticholic acid, modified bile acid

Galmed - Aramchol, Conjugate of Fatty acid and Fatty bile acid

Anti-fibrotic

Gilead - Simtuzumab, anti-fibrotic

Galectin - galectin proteins

Anti-Inflammatory + (anti-inflammatory, anti-diabetic, cholesterol control, FFA)

Immuron - Hyperimmune colostrum enriched with Anti-LPS Abs

Conatus - Emricassan, caspase protease inhibitor

Genfit - Peroxisome proliferator - activated receptor alpha

� IMM-124E is safe and may be best in class

4.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

ROBUST
PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

PIPELINE
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

Indication Research Pre-clinical Phase I Phase II Phase III

Traveller’s Diarrhea NASH (IMM-124E) ASH (IMM-124E)

Clostridium difficile infection Other Projects:

• Trial funded by NIH

27

• diabetes • Colitis/Crohn’s Disease

• Fibrosis

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

OVERVIEW
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH/ASH
----- End of picture text -----

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

US Hospitalisations Skyrocket Annually due to C.diff

• superbug

• more than US$3.2 billion in health care

==> picture [263 x 226] intentionally omitted <==

----- Start of picture text -----

85,700
----- End of picture text -----

Source: Agency for Healthcare Research and Quality 28

Comparative Values- Nasdaq Peers

• Immuron is significantly undervalued relative to peers listed on NASDAQ who are currently undertaking a Phase II study in NASH

Average Value for these Companies is over $100 Million

• Immuron is significantly undervalued relative to its peers listed on NASDAQ that currently have a C-Diff program in place.

Average Value of these companies is over $200 Million, although several are in Phase II or Phase III clinical trials.

At $20 Million Immuron represents a strong Value case with Two phase II studies, a C- Diff program, Travelan sales and a strong pipeline and safe platform.

5.

==> picture [721 x 271] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

TRAVELAN®

PIPELINE

OVERVIEW

==> picture [87 x 25] intentionally omitted <==

----- Start of picture text -----

NASH
----- End of picture text -----

==> picture [87 x 24] intentionally omitted <==

----- Start of picture text -----

SUMMARY
----- End of picture text -----

31

The Board and Management

Chairman

Non-Executive Director

Non-Executive Director

Director

Senior VP of Innovation

Clinical Director

Dr. Yaron Ilan Medical Officer

Dr. Yaron Ilan, MD, is a Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

Chief Scientific Officer

Development Manager

Manufacturing Quality Director

THANK YOU

==> picture [721 x 271] intentionally omitted <==